Genzyme recognizes World MS Day

GenzymeGenzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), marked World MS Day with activities across its global network and new programs designed to mobilize and inspire people living with multiple sclerosis. Genzyme is committed to a long-term partnership with the multiple sclerosis community and is advancing the field with a promising pipeline intended to address unmet medical needs and a world-class research program to bring forward future innovations in MS.

"To celebrate World MS Day, Genzyme employees are mobilizing globally to help increase understanding of multiple sclerosis and provide support for the community in very meaningful ways."

Developed by the Multiple Sclerosis International Federation (MSIF) and in its fourth year, World MS Day raises global awareness of multiple sclerosis and its impact on the lives of more than two million people around the world. Genzyme is a proud sponsor of the MSIF's World MS Day.

"To celebrate World MS Day, Genzyme employees are mobilizing globally to help increase understanding of multiple sclerosis and provide support for the community in very meaningful ways," said Genzyme President and CEO, David Meeker. "We are dedicated to partnering with the patient community as we work to redefine what's possible in MS."

Today in the United States, Genzyme and the National Multiple Sclerosis Society have launched the Everyday Matters program to enhance the outlook and overall well-being of those living with or affected by MS. The interactive online program draws on practical and scientific applications of positive psychology and provides free resources and strategies for individuals to overcome challenges and achieve personal goals. The Everyday Matters team includes renowned positive psychology expert Shawn Achor, along with Emmy-award winning producer Kristen Adams and Certified Life Coach Michelle Clos, both living with MS, and will work hand-in-hand with five individuals affected by MS from across the U.S.

Additional Genzyme World MS Day Initiatives
World MS Day is May 30, 2012 and serves as the only global awareness-raising campaign for multiple sclerosis, according to the MSIF. World MS Day was launched in 2009 and is celebrated in countries worldwide with activities designed to provide the public with information about MS and how it affects the lives of patients. Multiple sclerosis is a chronic, unpredictable and progressive disease of the central nervous system that is estimated to affect more than 2.1 million people worldwide. MS can lead to physical disability, cognitive impairment and fatigue.

Genzyme is supporting World MS Day globally with events and partnerships planned across sites in Spain, France, UK, Italy, U.S. and Netherlands that include fund-raising activities to raise money for local patient organizations and educational seminars led by MS advocacy representatives and healthcare providers. In addition, Genzyme France has joined the MS association, UNISEP, as a World MS Day partner, while Genzyme Spain developed the documentary RETOS ("Challenges") that explores the lives of three people living with MS. Site-wide events will include a book signing with an MS patient and author, a photo exhibition that links the World MS Day theme of 1000 Faces of MS, as well as presentations by patients.

About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...